Joaquı́n Mateo

24.2k total citations · 5 hit papers
148 papers, 6.1k citations indexed

About

Joaquı́n Mateo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Joaquı́n Mateo has authored 148 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Pulmonary and Respiratory Medicine, 84 papers in Oncology and 53 papers in Cancer Research. Recurrent topics in Joaquı́n Mateo's work include Prostate Cancer Treatment and Research (85 papers), PARP inhibition in cancer therapy (52 papers) and Cancer Genomics and Diagnostics (35 papers). Joaquı́n Mateo is often cited by papers focused on Prostate Cancer Treatment and Research (85 papers), PARP inhibition in cancer therapy (52 papers) and Cancer Genomics and Diagnostics (35 papers). Joaquı́n Mateo collaborates with scholars based in United Kingdom, Spain and United States. Joaquı́n Mateo's co-authors include Johann S. de Bono, David Olmos, Shahneen Sandhu, Karim Fizazi, Neal D. Shore, Oliver Sartor, Fred Saad, Neeraj Agarwal, Antoine Thiery-Vuillemin and Carrie A. Adelman and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Joaquı́n Mateo

142 papers receiving 6.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib for Metastatic Castration-Resistant Prostate Cancer

2020 1.4k citations Johann S. de Bono, Joaquı́n Mateo et al. New England Journal of Medicine profile →
A decade of clinical development of PARP inhibitors in perspective

2019 495 citations Joaquı́n Mateo, Christopher J. Lord et al. Annals of Oncology profile →
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

2020 474 citations Maha Hussain, Joaquı́n Mateo et al. New England Journal of Medicine profile →
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

2018 391 citations Joaquı́n Mateo, Debyani Chakravarty et al. Annals of Oncology profile →
Delivering precision oncology to patients with cancer

2022 197 citations Joaquı́n Mateo, Lotte Steuten et al. Nature Medicine profile →

Peers

Countries citing papers authored by Joaquı́n Mateo

Since Specialization

Citations

This map shows the geographic impact of Joaquı́n Mateo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joaquı́n Mateo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joaquı́n Mateo more than expected).

Fields of papers citing papers by Joaquı́n Mateo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joaquı́n Mateo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joaquı́n Mateo. The network helps show where Joaquı́n Mateo may publish in the future.

Co-authorship network of co-authors of Joaquı́n Mateo

This figure shows the co-authorship network connecting the top 25 collaborators of Joaquı́n Mateo. A scholar is included among the top collaborators of Joaquı́n Mateo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joaquı́n Mateo. Joaquı́n Mateo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identification of SARS-CoV-2 3CLpro inhibitors from marine actinomycetes through integrated phylogeny-based metabolomics with functional screening and bioinformatic analysis 2025 ·Scientific Reports ·Doralyn S. Dalisay, Joaquı́n Mateo, (unknown), (unknown), (unknown), Luis Guzmán, (unknown), Jamia Azdina Jamal	0
2	A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer 2025 ·Cell Reports Medicine ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Cristina Viaplana, (unknown), Joaquı́n Mateo, (unknown), (unknown), Francesc Salvà, Jaume Capdevila, Elena Élez, (unknown), Elena Garralda, Raquel Pérez-López	3
3	Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer 2025 ·Molecular Cancer Therapeutics ·(unknown), (unknown), (unknown), Daniel Aguilar, (unknown), Sara Arce‐Gallego, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Irene Casanova‐Salas, Marcos Malumbres, Joan Carles, (unknown), Andrea Bernardos, Ramón Martínez‐Máñez, Joaquı́n Mateo, Nicolás Herranz	1
4	Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis 2025 ·Annals of Oncology ·Carmine Valenza, (unknown), Yi Gong, Pietro De Placido, (unknown), H. Ortíz, Dario Trapani, Fabio Conforti, (unknown), S. Peters, Joaquı́n Mateo, Vivek Subbiah, Heather A. Parsons, Ann H. Partridge, Giuseppe Curigliano	5
5	Metastatic hormone-naïve prostate cancer: a distinct biological entity 2024 ·Trends in cancer ·(unknown), (unknown), Natalia Martín-Martín, Joaquı́n Mateo, Arkaitz Carracedo	3
6	CRISPR/Cas9 screens identify LIG1 as a sensitizer of PARP inhibitors in castration-resistant prostate cancer 2024 ·Journal of Clinical Investigation ·(unknown), Francesca Lorenzin, Francesco Orlando, Ubaldo Gioia, Giuseppe D’Amato, (unknown), (unknown), Davide Prandi, Frédéric R. Santer, Helmut Klocker, Fabrizio d’Adda di Fagagna, Joaquı́n Mateo, Francesca Demichelis	2
7	Cyclophilin D plays a critical role in the survival of senescent cells 2024 ·The EMBO Journal ·Margherita Protasoni, (unknown), Camille Stephan‐Otto Attolini, (unknown), Nicolás Herranz, Joaquı́n Mateo, Sergio Ruiz, Óscar Fernández-Capetillo, Marta Kovatcheva, Manuel Serrano	12
8	Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment 2023 ·Clinical & Translational Oncology ·Rafael Morales‐Barrera, Guillermo Villacampa, (unknown), (unknown), (unknown), Teresa Bonfill, Cristina Suárez, (unknown), Joaquı́n Mateo, (unknown), Montserrat Domènech, Javier Puente, Joan Carles	1
9	Delivering precision oncology to patients with cancer breakdown → 2022 ·Nature Medicine ·Joaquı́n Mateo, Lotte Steuten, Philippe Aftimos, Fabrice André, D. M. Davies, Elena Garralda, Jan Geißler, Don Husereau, (unknown), Nicola Normanno, Jorge S. Reis‐Filho, Stephen Stefani, David M. Thomas, C. Benedikt Westphalen, Emile E. Voest	197
10	Detection of BRCA1 , BRCA2 , and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound 2022 ·Clinical Cancer Research ·Kim N., Alan Barnicle, (unknown), Zhongwu Lai, Claire Corcoran, J. Carl Barrett, Carrie A. Adelman, Ping Qiu, Ashley Easter, Simon Dearden, Geoffrey R. Oxnard, Neeraj Agarwal, Arun Azad, Johann S. de Bono, Joaquı́n Mateo, David Olmos, Antoine Thiery-Vuillemin, Elizabeth A. Harrington	46
11	Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease 2022 ·Frontiers in Oncology ·Cristina Suárez, (unknown), (unknown), Rafael Morales‐Barrera, (unknown), Joaquı́n Mateo, (unknown), David Lorente, Enrique Trilla, Joan Carles	12
12	Metastatic nonclear renal cell carcinoma current review in evolving treatment strategies 2021 ·Current Opinion in Urology ·Cristina Suárez, (unknown), Rafael Morales‐Barrera, (unknown), Joaquı́n Mateo, Joan Carles	3
13	First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors 2020 ·Clinical Cancer Research ·(unknown), Rajiv Kumar, Dionysis Papadatos-Pastos, Joaquı́n Mateo, Jessica Brown, Alvaro Ingles Garces, Ruth Ruddle, Shaun Decordova, Simone Jueliger, Roberta Ferraldeschi, Óscar Maiques, Victoria Sanz‐Moreno, Paul S. Jones, Stephanie Traub, Gavin Halbert, (unknown), Karen E. Swales, Florence I. Raynaud, Michelle D. Garrett, Udai Banerji	52
14	Olaparib for Metastatic Castration-Resistant Prostate Cancer breakdown → 2020 ·New England Journal of Medicine ·Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Kim N., Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Niven Mehra, Carsten Goessl, Jinyu Kang, Joseph E. Burgents, Wenting Wu, Alexander Kohlmann, Carrie A. Adelman, Maha Hussain	1397
15	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer breakdown → 2020 ·New England Journal of Medicine ·Maha Hussain, Joaquı́n Mateo, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Kim N., Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Guilhem Roubaud, Mustafa Özgüroğlu, Jinyu Kang, Joseph E. Burgents, Christopher Gresty, Claire Corcoran, Carrie A. Adelman, Johann S. de Bono	474
16	A decade of clinical development of PARP inhibitors in perspective breakdown → 2019 ·Annals of Oncology ·Joaquı́n Mateo, Christopher J. Lord, Violeta Serra, Andrew Tutt, Judith Balmañà, Marta Castroviejo‐Bermejo, Cristina Cruz, Ana Oaknin, Stan B. Kaye, Johann S. de Bono	495
17	RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer 2018 ·Clinical Cancer Research ·Daniel Nava Rodrigues, Nicola Casiraghi, Alessandro Romanel, Mateus Crespo, Susana Miranda, Pasquale Rescigno, Ines Figueiredo, Ruth Riisnaes, Suzanne Carreira, Semini Sumanasuriya, Paola Gasperini, Adam Sharp, Joaquı́n Mateo, (unknown), Christopher McNair, Matthew J. Schiewer, Karen E. Knudsen, Gunther Boysen, Francesca Demichelis, Johann S. de Bono	44
18	A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) breakdown → 2018 ·Annals of Oncology ·Joaquı́n Mateo, Debyani Chakravarty, Rodrigo Dienstmann, S. Jezdic, Abel González-Pérez, Núria López-Bigas, Charlotte K.Y. Ng, Philippe L. Bédard, Giampaolo Tortora, J.-Y. Douillard, Eliezer M. Van Allen, Nikolaus Schultz, Charles Swanton, Fabrice André, Lajos Pusztai	391
19	Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer 2016 ·European Urology ·David Lorente, David Olmos, Joaquı́n Mateo, Diletta Bianchini, George Seed, Martin Fleisher, Daniel C. Danila, Penny Flohr, Mateus Crespo, Ines Figueiredo, Susana Miranda, Kurt Baeten, Arturo Molina, Thian Kheoh, Robert McCormack, Leon W.M.M. Terstappen, Howard I. Scher, Johann S. de Bono	113
20	Switching and withdrawing hormonal agents for castration-resistant prostate cancer 2015 ·Nature Reviews Urology ·David Lorente, Joaquı́n Mateo, Zafeiris Zafeiriou, Alan D. Smith, Shahneen Sandhu, Roberta Ferraldeschi, Johann S. de Bono	58

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact